{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:37:54Z","timestamp":1777361874908,"version":"3.51.4"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is a subtype of breast cancer that presents significant therapeutic challenges due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. As a result, conventional hormonal and targeted therapies are largely ineffective, underscoring the urgent need for novel treatment strategies. \u03b3\u03b4T cells, known for their robust anti-tumor properties, show considerable potential in TNBC treatment as they can identify and eliminate tumor cells without reliance on MHC restrictions. These cells demonstrate extensive proliferation both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, and can directly target tumors through cytotoxic effects or indirectly by promoting other immune responses. Studies suggest that expansion and adoptive transfer strategies targeting V\u03b42 and V\u03b41 \u03b3\u03b4T cell subtypes have shown promise in preclinical TNBC models. This review compiles and discusses the existing literature on the primary subgroups of \u03b3\u03b4T cells, their roles in cancer therapy, their contributions to tumor cell cytotoxicity and immune modulation, and proposes potential strategies for future \u03b3\u03b4T cell-based immunotherapies in TNBC.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1420107","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T04:34:05Z","timestamp":1718166845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The therapeutic role of \u03b3\u03b4T cells in TNBC"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenjing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.03.016","article-title":"The spectrum of triple-negative breast disease: high- and low-grade lesions","volume":"187","author":"Geyer","year":"2017","journal-title":"Am J Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523\u2013022-00468\u20130","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02572","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"41","author":"Liedtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115866","article-title":"Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer","volume":"169","author":"Wang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects","volume":"32","author":"Jia","year":"2017","journal-title":"Drug Resist Update"},{"key":"B6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options","author":"So","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040765","article-title":"Clinicopathological correlates of \u03b3\u03b4T cell infiltration in triple-negative breast cancer","volume":"13","author":"Boissi\u00e8re-Michot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat\u00a0Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.06.004","article-title":"The ambiguous role of \u03b3\u03b4T lymphocytes in antitumor immunity","volume":"38","author":"Chitadze","year":"2017","journal-title":"Trends Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2013019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2013022-00396\u20139","article-title":"\u03b3\u03b4T cells share the spotlight in cancer","volume":"3","author":"Conejo-Garcia","year":"2022","journal-title":"Nat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2013022-00722\u20131","article-title":"The emerging roles of \u03b3\u03b4T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2013020-00452\u20134","article-title":"\u03b3\u03b4T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891687","article-title":"Comparing mouse and human tissue-resident \u03b3\u03b4T cells","volume":"13","author":"Qu","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000211","article-title":"HMGN2: an antitumor effector molecule of \u03b3\u03b4T cells","volume":"41","author":"Chen","year":"2018","journal-title":"J Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.dci.2011.12.013","article-title":"Regulatory mechanisms of thymus and T cell development","volume":"39","author":"Ma","year":"2013","journal-title":"Dev Comp Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302259","article-title":"An overview of the intrathymic intricacies of T cell development","volume":"192","author":"Shah","year":"2014","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2021.06.006","article-title":"Differentiation and functional plasticity of gamma-delta (\u03b3\u03b4)\u2009T cells under homeostatic and disease conditions","volume":"136","author":"Giri","year":"2021","journal-title":"Mol Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.06.016","article-title":"1. Lymphocytes","volume":"121","author":"Larosa","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2013018-0020\u20138","article-title":"Regulatory mechanisms in T cell receptor signalling","volume":"18","author":"Gaud","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.01.007","article-title":"Thymic determinants of \u03b3\u03b4T cell differentiation","volume":"38","author":"Mu\u00f1oz-Ruiz","year":"2017","journal-title":"Trends Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00042","article-title":"Regulation of \u03b3\u03b4T cell effector diversification in the thymus","volume":"11","author":"Parker","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017\u201308-752162","article-title":"The potential role of \u03b3\u03b4T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T Cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e5","article-title":"Heterogeneity of human \u03b3\u03b4T cells and their role in cancer immunity","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2011.553595","article-title":"Human V\u03b41 \u03b3\u03b4T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells","volume":"13","author":"Siegers","year":"2011","journal-title":"Cytotherapy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.763773","article-title":"Bone marrow-resident V\u03b41 T cells co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125884","article-title":"NKp46-expressing human gut-resident intraepithelial V\u03b41 T cell subpopulation exhibits high antitumor activity against colorectal cancer","volume":"4","author":"Mikulak","year":"2019","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12904","article-title":"Deciphering human \u03b3\u03b4T cell response in cancer: Lessons from tumor-infiltrating \u03b3\u03b4T cells","volume":"298","author":"Lo Presti","year":"2020","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.02.002","article-title":"Human V\u03b43(+) \u03b3\u03b4T cells induce maturation and IgM secretion by B cells","volume":"196","author":"Petrasca","year":"2018","journal-title":"Immunol Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000225","article-title":"IL-21 increases the reactivity of allogeneic human V\u03b39V\u03b42 T cells against primary glioblastoma tumors","volume":"41","author":"Joalland","year":"2018","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425\u2013019-0501\u20138","article-title":"Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma","volume":"7","author":"Alnaggar","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01600","article-title":"Immune effects of \u03b3\u03b4T cells in colorectal cancer: A review","volume":"11","author":"Ma","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11090923","article-title":"\u03b1\u03b2-T cells engineered to express \u03b3\u03b4-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression","volume":"11","author":"Strijker","year":"2021","journal-title":"J Pers Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis253","article-title":"Phenotypic and functional characterization of human \u03b3\u03b4T-cell subsets in response to influenza A viruses","volume":"205","author":"Qin","year":"2012","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.73","article-title":"Human regulatory \u03b3\u03b4T cells and their functional plasticity in the tumor microenvironment","volume":"15","author":"Chen","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392\u2013023-01653\u20138","article-title":"\u03b3\u03b4T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12272\u2013019-01146\u20139","article-title":"T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer","volume":"42","author":"Chang","year":"2019","journal-title":"Arch Pharm Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202369","article-title":"Tumor-derived \u03b3\u03b4 regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence","volume":"190","author":"Ye","year":"2013","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600\u2013065X.2006.00479.x","article-title":"Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens","volume":"215","author":"Morita","year":"2007","journal-title":"Immunol Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.09.001","article-title":"Monocytes and gammadelta T cells: close encounters in microbial infection","volume":"30","author":"Eberl","year":"2009","journal-title":"Trends Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051305","article-title":"\u03b3\u03b4T cells: the ideal tool for cancer immunotherapy","volume":"9","author":"Yazdanifar","year":"2020","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.immuni.2004.11.012","article-title":"Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I","volume":"22","author":"Scotet","year":"2005","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904024","article-title":"F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells","volume":"184","author":"Mookerjee-Basu","year":"2010","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051206","article-title":"The role of human \u03b3\u03b4T cells in anti-tumor immunity and their potential for cancer immunotherapy","volume":"9","author":"Liu","year":"2020","journal-title":"Cells"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.384354","article-title":"The molecular basis for modulation of human V\u03b39V\u03b42 T cell responses by CD277\/butyrophilin-3 (BTN3A)-specific antibodies","volume":"287","author":"Palakodeti","year":"2012","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2013023-06525\u20133","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.09.003","article-title":"\u03b3\u03b4T cell surveillance via CD1 molecules","volume":"35","author":"Luoma","year":"2014","journal-title":"Trends Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e22892","DOI":"10.4161\/onci.22892","article-title":"Tumor cell recognition by \u03b3\u03b4T lymphocytes: T-cell receptor vs. NK-cell receptors","volume":"2","author":"Correia","year":"2013","journal-title":"Oncoimmunology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00851","article-title":"Working in \"NK mode\": natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by \u03b3\u03b4T cells","volume":"9","author":"Silva-Santos","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00015","article-title":"Five layers of receptor signaling in \u03b3\u03b4T-cell differentiation and activation","volume":"6","author":"Ribeiro","year":"2015","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.it.2016.08.015","article-title":"Regulation of NKG2D expression and signaling by endocytosis","volume":"37","author":"Molfetta","year":"2016","journal-title":"Trends Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.11.001","article-title":"Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense","volume":"29","author":"Satoh-Takayama","year":"2008","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.404","article-title":"Expression and function of the natural cytotoxicity receptor NKp46 on circulating Malignant CD4+ T lymphocytes of S\u00e9zary syndrome patients","volume":"131","author":"Bensussan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011\u201302-339135","article-title":"Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells","volume":"118","author":"Correia","year":"2011","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.03.513","article-title":"CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis","volume":"128","author":"Chen","year":"2008","journal-title":"Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.28","article-title":"The promise of \u03b3\u03b4T cells and the \u03b3\u03b4T cell receptor for cancer immunotherapy","volume":"12","author":"Legut","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23365","article-title":"V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs\u2013rituximab and trastuzumab","volume":"122","author":"Tokuyama","year":"2008","journal-title":"Int J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.023","article-title":"Early reconstitution of NK and \u03b3\u03b4T cells and its implication for the design of post-transplant immunotherapy","volume":"24","author":"de Witte","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00814","article-title":"Tribody [(HER2)(2)xCD16] is more effective than trastuzumab in enhancing \u03b3\u03b4T cell and natural killer cell cytotoxicity against HER2-expressing cancer cells","volume":"9","author":"Oberg","year":"2018","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004\u201301-0331","article-title":"FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s12967\u2013017-1378\u20132","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor\u2013mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.Ccr-07\u20134912","article-title":"Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma","volume":"14","author":"Alexander","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02044","article-title":"TRAIL-receptor 4 modulates \u03b3\u03b4T cell-cytotoxicity toward cancer cells","volume":"10","author":"Tawfik","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","article-title":"IFN-\u03b3 enhances HOS and U2OS cell lines susceptibility to \u03b3\u03b4T cell-mediated killing through the Fas\/Fas ligand pathway","volume":"11","author":"Li","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.01.001","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser","year":"2009","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14292","article-title":"Nonapoptotic functions of Fas\/CD95 in the immune response","volume":"285","author":"Gu\u00e9gan","year":"2018","journal-title":"FEBS J"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619954","article-title":"The dual roles of human \u03b3\u03b4T cells: anti-tumor or tumor-promoting","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2013015-1700-x","article-title":"Myeloid molecular characteristics of human \u03b3\u03b4T cells support their acquisition of tumor antigen-presenting capacity","volume":"64","author":"Muto","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20136066.Cir-21\u20130952","article-title":"IL12\/18\/21 preactivation enhances the antitumor efficacy of expanded \u03b3\u03b4T cells and overcomes resistance to anti-PD-L1 treatment","volume":"11","author":"Teo","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838354","article-title":"A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury","volume":"38","author":"Rhodes","year":"2008","journal-title":"Eur J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202959","article-title":"Proinflammatory V\u03b42+ T cells populate the human intestinal mucosa and enhance IFN-\u03b3 production by colonic \u03b1\u03b2 T cells","volume":"191","author":"McCarthy","year":"2013","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142017","article-title":"IL-21 enhances the potential of human \u03b3\u03b4T cells to provide B-cell help","volume":"42","author":"Bansal","year":"2012","journal-title":"Eur J Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of gammadelta T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.4979","article-title":"Cutting edge: gamma delta T cells provide help to B cells with altered clonotypes and are capable of inducing Ig gene hypermutation","volume":"171","author":"Zheng","year":"2003","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.8.5290","article-title":"CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production","volume":"177","author":"Caccamo","year":"2006","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009\u201307-234211","article-title":"Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement","volume":"116","author":"Maniar","year":"2010","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011\u201301-328526","article-title":"DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by \u03b3\u03b4T lymphocytes","volume":"118","author":"Nussbaumer","year":"2011","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1386","article-title":"Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation","volume":"176","author":"Devilder","year":"2006","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.5656","article-title":"Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand","volume":"175","author":"Collins","year":"2005","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00861","article-title":"Potent bidirectional cross-talk between plasmacytoid dendritic cells and \u03b3\u03b4T cells through BTN3A, type I\/II IFNs and immune checkpoints","volume":"11","author":"Girard","year":"2020","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894315","article-title":"\u03b3\u03b4T cells in the tumor microenvironment-interactions with other immune cells","volume":"13","author":"Chan","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2013020-02805\u20133","article-title":"The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies","volume":"70","author":"Galati","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403424111","article-title":"Murine CD27(-) V\u03b36(+) \u03b3\u03b4T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages","volume":"111","author":"Rei","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B92","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13938","article-title":"IL-17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K\/AKT signalling pathway","volume":"23","author":"Zheng","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/bcr2195","article-title":"IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines","volume":"10","author":"Zhu","year":"2008","journal-title":"Breast Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30134","article-title":"IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients","volume":"139","author":"Patil","year":"2016","journal-title":"Int J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30109","article-title":"Regulatory and effector functions of gamma\u2013delta (\u03b3\u03b4) T cells and their therapeutic potential in adoptive cellular therapy for cancer","volume":"139","author":"Paul","year":"2016","journal-title":"Int J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902574","article-title":"IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells","volume":"184","author":"He","year":"2010","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","article-title":"\u03b3\u03b4T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer","volume":"40","author":"Wu","year":"2014","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20135472.Can-13\u20132534","article-title":"IL-17A produced by \u03b3\u03b4T cells promotes tumor growth in hepatocellular carcinoma","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/0008\u20135472.Can-14\u20133228","article-title":"The emerging Protumor role of \u03b3\u03b4T lymphocytes: implications for cancer immunotherapy","volume":"75","author":"Rei","year":"2015","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2009.06.005","article-title":"Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human","volume":"125","author":"Kang","year":"2009","journal-title":"Immunol Lett"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s12276\u2013021-00576\u20130","article-title":"Function of \u03b3\u03b4T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00018\u2013013-1467\u20131","article-title":"Phenotype and regulation of immunosuppressive V\u03b42-expressing \u03b3\u03b4T cells","volume":"71","author":"Peters","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061537","article-title":"Diversity of tumor-infiltrating, \u03b3\u03b4T-cell abundance in solid cancers","volume":"9","author":"Chabab","year":"2020","journal-title":"Cells"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv571","article-title":"Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer","volume":"27","author":"Pruneri","year":"2016","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1470\u20132045(17)30904-x","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax9364","article-title":"An innate-like V\u03b41(+) \u03b3\u03b4T cell compartment in the human breast is associated with remission in triple-negative breast cancer","volume":"11","author":"Wu","year":"2019","journal-title":"Sci Transl Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1038\/s41598\u2013021-83913\u20137","article-title":"CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer","volume":"11","author":"Craven","year":"2021","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20136066.Cir-19\u20130513","article-title":"\u03b3\u03b4T-cell receptors derived from breast cancer-infiltrating T lymphocytes mediate antitumor reactivity","volume":"8","author":"Janssen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.3ma0420\u2013278rr","article-title":"Identification of a regulatory V\u03b41 gamma delta T cell subpopulation expressing CD73 in human breast cancer","volume":"107","author":"Chabab","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: A review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045\u2013022-01341\u20130","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2013011-1021\u20137","article-title":"Phase I\/II study of adoptive transfer of \u03b3\u03b4T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B114","author":"Yazdanifar","year":""},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27191","article-title":"Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of V\u03b39V\u03b42 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide","volume":"99","author":"Jullien","year":"2024","journal-title":"Am J Hematol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41423\u2013020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2013010-0879\u20130","article-title":"Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors","volume":"59","author":"Bennouna","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.12.017","article-title":"Combined effects of neoadjuvant letrozole and zoledronic acid on \u03b3\u03b4T cells in postmenopausal women with early-stage breast cancer","volume":"38","author":"Sugie","year":"2018","journal-title":"Breast"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28217","article-title":"Human V\u03b32V\u03b42 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors","volume":"133","author":"Aggarwal","year":"2013","journal-title":"Int J Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/nu11050977","article-title":"The effect of vitamin C (Ascorbic acid) in the treatment of patients with cancer: A systematic review","volume":"11","author":"van Gorkom","year":"2019","journal-title":"Nutrients"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41423\u2013019-0247\u20138","article-title":"Vitamin C promotes the proliferation and effector functions of human \u03b3\u03b4T cells","volume":"17","author":"Kouakanou","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8707","article-title":"High-dose vitamin C enhances cancer immunotherapy","volume":"12","author":"Magr\u00ec","year":"2020","journal-title":"Sci Transl Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41423\u2013020-0515\u20137","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568\u2013019-0153\u20135","article-title":"\u03b3\u03b4T cells: pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.Ccr-16\u20130597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin\u00a0Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174803","article-title":"Gamma delta (\u03b3\u03b4) T cells in cancer immunotherapy; where it comes from, where it will go","volume":"919","author":"Deng","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20136066.Cir-22\u20130296","article-title":"Breast cancer stem cell-derived tumors escape from \u03b3\u03b4T-cell immunosurveillance in vivo by modulating \u03b3\u03b4T-cell ligands","volume":"11","author":"Raute","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20137163.Mct-20\u20130385","article-title":"Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.07.044","article-title":"CAR T-cell therapy for triple-negative breast cancer: Where we are","volume":"491","author":"Xie","year":"2020","journal-title":"Cancer Lett"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030404","article-title":"Chimeric antigen receptor beyond CAR-T cells","volume":"13","author":"Qin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2112898","article-title":"Folate receptor-alpha targeted 7x19 CAR-\u03b3\u03b4T suppressed triple-negative breast cancer xenograft model in mice","volume":"2022","author":"Ye","year":"2022","journal-title":"J\u00a0Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943\u2013023-01722\u20130","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20135472.Can-13\u20130675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.04.009","article-title":"\u03b3\u03b4T cell activation by bispecific antibodies","volume":"296","author":"Oberg","year":"2015","journal-title":"Cell Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021\u2013003850","article-title":"Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds","volume":"9","author":"van Diest","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.12.014","article-title":"Large-scale expansion of V\u03b39V\u03b42 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells","volume":"20","author":"Xiao","year":"2018","journal-title":"Cytotherapy"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112896","article-title":"Metabolic changes in tumor microenvironment: how could they affect \u03b3\u03b4T cells functions","volume":"10","author":"Corsale","year":"2021","journal-title":"Cells"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01395","article-title":"\u03b3\u03b4T cells and tumor microenvironment: from immunosurveillance to tumor evasion","volume":"9","author":"Lo Presti","year":"2018","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2023.08.002","article-title":"Proactive and reactive roles of TGF-\u03b2 in cancer","volume":"95","author":"Kuburich","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123090","article-title":"Regulations of tumor microenvironment by prostaglandins","volume":"15","author":"Nie","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25074126","article-title":"Soluble NKG2DLs are elevated in breast cancer patients and associate with disease outcome","volume":"25","author":"Seller","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.104","article-title":"Cytotoxic and regulatory properties of circulating V\u03b41+ \u03b3\u03b4T cells: a new player on the cell therapy field","volume":"22","author":"Siegers","year":"2014","journal-title":"Mol Ther"},{"key":"B149","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/cmi.2012.39","article-title":"What lessons can be learned from \u03b3\u03b4T cell-based cancer immunotherapy trials","volume":"10","author":"Fourni\u00e9","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph8010040","article-title":"\u03b3\u03b4T cell immunotherapy-A review","volume":"8","author":"Kobayashi","year":"2015","journal-title":"Pharm (Basel)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049119","article-title":"Evolved to protect, designed to destroy: IL-17-producing \u03b3\u03b4T cells in infection, inflammation, and cancer","volume":"51","author":"Agerholm","year":"2021","journal-title":"Eur J Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000680","article-title":"Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a \u03b3\u03b4T-cell subtype associated with good clinical outcome","volume":"4","author":"Boufea","year":"2021","journal-title":"Life Sci Alliance"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1420107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T04:34:16Z","timestamp":1718166856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1420107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":152,"alternative-id":["10.3389\/fimmu.2024.1420107"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1420107","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"article-number":"1420107"}}